Point72 Europe London LLP Buys Shares of 192,694 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Point72 Europe London LLP purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 192,694 shares of the company's stock, valued at approximately $6,149,000. Point72 Europe London LLP owned about 0.15% of Apellis Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in APLS. Xponance Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 5.6% during the 4th quarter. Xponance Inc. now owns 14,072 shares of the company's stock valued at $449,000 after purchasing an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after acquiring an additional 758 shares during the last quarter. Signaturefd LLC grew its stake in shares of Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock worth $37,000 after buying an additional 918 shares during the last quarter. US Bancorp DE grew its stake in shares of Apellis Pharmaceuticals by 70.0% in the fourth quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after purchasing an additional 1,327 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Apellis Pharmaceuticals by 19.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,615 shares of the company's stock valued at $307,000 after acquiring an additional 1,578 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Needham & Company LLC dropped their price objective on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Scotiabank dropped their target price on Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating for the company in a report on Thursday, May 8th. Robert W. Baird lowered their price objective on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Mizuho cut their price target on shares of Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a report on Wednesday. Finally, Wedbush cut their target price on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Nine investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $40.42.

Apellis Pharmaceuticals Stock Down 3.4%

Apellis Pharmaceuticals stock opened at $16.70 on Thursday. Apellis Pharmaceuticals, Inc. has a 1-year low of $16.41 and a 1-year high of $43.99. The business has a fifty day moving average price of $20.66 and a 200-day moving average price of $26.85. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of -8.23 and a beta of 0.73.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same period in the prior year, the business posted ($0.54) EPS. Apellis Pharmaceuticals's revenue was down 3.2% compared to the same quarter last year. Equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares in the company, valued at approximately $3,482,123. This represents a 3.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.50% of the stock is owned by company insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.